Erlotinib for metastatic non-small-cell lung cancer: First-, second- or third-line setting - Does it matter? A single-institution experience

Sikander Ailawadhi, Lyudmyla Derby, Raj Natarajan, Gerald Fetterly, Mary Reid, Nithya Ramnath

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background: Erlotinib is approved as treatment for metastatic non-small-cell lung cancer (NSCLC), following failure of initial therapy. Studies to define patients that derive maximal benefit from erlotinib have not dictated current practice. Methods: We retrospectively analyzed the prescription patterns and outcomes related to erlotinib use for NSCLC in a comprehensive cancer center. Results: Of 137 consecutive patients treated with erlotinib over 2 years, 116 were evaluable. Median age was 66 years, 63% females, most common histology was adenocarcinoma (n = 58). Seventy-nine patients presented with stage IIIB-IV disease, 37 with recurrent disease. There were 109 smokers. Erlotinib was given first line in 31 (27%), second line in 52 (45%) and third line in 33 (28%) patients. Daily erlotinib dose was 100 mg in 21 (18%) and 150 mg in 91 (82%) patients. Median duration of treatment was 8 weeks (range 1-72). Median overall survival (OS) from initiation of erlotinib was 5.4 months (range 0.2-27.8). There was no significant difference in median survival by disease stage (recurrent vs. de novo IIIB-IV) (p = 0.201), whether erlotinib was used as first-, second-, third-line therapy (p = 0.971) or at different doses (100 vs. 150 mg daily dose) (p = 0.579). Conclusions: OS after erlotinib use was not different, whether used as first-, second- or third-line therapy, whether patients had recurrent metastatic NSCLC or de novo stage IV disease, or if erlotinib was used at a dose of 100 or 150 mg daily.

Original languageEnglish (US)
Pages (from-to)85-90
Number of pages6
JournalOncology
Volume76
Issue number2
DOIs
StatePublished - Feb 2009
Externally publishedYes

Fingerprint

Non-Small Cell Lung Carcinoma
Survival
Erlotinib Hydrochloride
Therapeutics
Prescriptions
Histology
Adenocarcinoma

Keywords

  • Erlotinib
  • Metastatic non-small-cell lung cancer
  • Non-small-cell lung cancer
  • Tarceva

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Erlotinib for metastatic non-small-cell lung cancer : First-, second- or third-line setting - Does it matter? A single-institution experience. / Ailawadhi, Sikander; Derby, Lyudmyla; Natarajan, Raj; Fetterly, Gerald; Reid, Mary; Ramnath, Nithya.

In: Oncology, Vol. 76, No. 2, 02.2009, p. 85-90.

Research output: Contribution to journalArticle

Ailawadhi, Sikander ; Derby, Lyudmyla ; Natarajan, Raj ; Fetterly, Gerald ; Reid, Mary ; Ramnath, Nithya. / Erlotinib for metastatic non-small-cell lung cancer : First-, second- or third-line setting - Does it matter? A single-institution experience. In: Oncology. 2009 ; Vol. 76, No. 2. pp. 85-90.
@article{7e4ea90484a7489582e9201bf641c2a6,
title = "Erlotinib for metastatic non-small-cell lung cancer: First-, second- or third-line setting - Does it matter? A single-institution experience",
abstract = "Background: Erlotinib is approved as treatment for metastatic non-small-cell lung cancer (NSCLC), following failure of initial therapy. Studies to define patients that derive maximal benefit from erlotinib have not dictated current practice. Methods: We retrospectively analyzed the prescription patterns and outcomes related to erlotinib use for NSCLC in a comprehensive cancer center. Results: Of 137 consecutive patients treated with erlotinib over 2 years, 116 were evaluable. Median age was 66 years, 63{\%} females, most common histology was adenocarcinoma (n = 58). Seventy-nine patients presented with stage IIIB-IV disease, 37 with recurrent disease. There were 109 smokers. Erlotinib was given first line in 31 (27{\%}), second line in 52 (45{\%}) and third line in 33 (28{\%}) patients. Daily erlotinib dose was 100 mg in 21 (18{\%}) and 150 mg in 91 (82{\%}) patients. Median duration of treatment was 8 weeks (range 1-72). Median overall survival (OS) from initiation of erlotinib was 5.4 months (range 0.2-27.8). There was no significant difference in median survival by disease stage (recurrent vs. de novo IIIB-IV) (p = 0.201), whether erlotinib was used as first-, second-, third-line therapy (p = 0.971) or at different doses (100 vs. 150 mg daily dose) (p = 0.579). Conclusions: OS after erlotinib use was not different, whether used as first-, second- or third-line therapy, whether patients had recurrent metastatic NSCLC or de novo stage IV disease, or if erlotinib was used at a dose of 100 or 150 mg daily.",
keywords = "Erlotinib, Metastatic non-small-cell lung cancer, Non-small-cell lung cancer, Tarceva",
author = "Sikander Ailawadhi and Lyudmyla Derby and Raj Natarajan and Gerald Fetterly and Mary Reid and Nithya Ramnath",
year = "2009",
month = "2",
doi = "10.1159/000187427",
language = "English (US)",
volume = "76",
pages = "85--90",
journal = "Oncology",
issn = "0030-2414",
publisher = "UBM Medica Healthcare Publications",
number = "2",

}

TY - JOUR

T1 - Erlotinib for metastatic non-small-cell lung cancer

T2 - First-, second- or third-line setting - Does it matter? A single-institution experience

AU - Ailawadhi, Sikander

AU - Derby, Lyudmyla

AU - Natarajan, Raj

AU - Fetterly, Gerald

AU - Reid, Mary

AU - Ramnath, Nithya

PY - 2009/2

Y1 - 2009/2

N2 - Background: Erlotinib is approved as treatment for metastatic non-small-cell lung cancer (NSCLC), following failure of initial therapy. Studies to define patients that derive maximal benefit from erlotinib have not dictated current practice. Methods: We retrospectively analyzed the prescription patterns and outcomes related to erlotinib use for NSCLC in a comprehensive cancer center. Results: Of 137 consecutive patients treated with erlotinib over 2 years, 116 were evaluable. Median age was 66 years, 63% females, most common histology was adenocarcinoma (n = 58). Seventy-nine patients presented with stage IIIB-IV disease, 37 with recurrent disease. There were 109 smokers. Erlotinib was given first line in 31 (27%), second line in 52 (45%) and third line in 33 (28%) patients. Daily erlotinib dose was 100 mg in 21 (18%) and 150 mg in 91 (82%) patients. Median duration of treatment was 8 weeks (range 1-72). Median overall survival (OS) from initiation of erlotinib was 5.4 months (range 0.2-27.8). There was no significant difference in median survival by disease stage (recurrent vs. de novo IIIB-IV) (p = 0.201), whether erlotinib was used as first-, second-, third-line therapy (p = 0.971) or at different doses (100 vs. 150 mg daily dose) (p = 0.579). Conclusions: OS after erlotinib use was not different, whether used as first-, second- or third-line therapy, whether patients had recurrent metastatic NSCLC or de novo stage IV disease, or if erlotinib was used at a dose of 100 or 150 mg daily.

AB - Background: Erlotinib is approved as treatment for metastatic non-small-cell lung cancer (NSCLC), following failure of initial therapy. Studies to define patients that derive maximal benefit from erlotinib have not dictated current practice. Methods: We retrospectively analyzed the prescription patterns and outcomes related to erlotinib use for NSCLC in a comprehensive cancer center. Results: Of 137 consecutive patients treated with erlotinib over 2 years, 116 were evaluable. Median age was 66 years, 63% females, most common histology was adenocarcinoma (n = 58). Seventy-nine patients presented with stage IIIB-IV disease, 37 with recurrent disease. There were 109 smokers. Erlotinib was given first line in 31 (27%), second line in 52 (45%) and third line in 33 (28%) patients. Daily erlotinib dose was 100 mg in 21 (18%) and 150 mg in 91 (82%) patients. Median duration of treatment was 8 weeks (range 1-72). Median overall survival (OS) from initiation of erlotinib was 5.4 months (range 0.2-27.8). There was no significant difference in median survival by disease stage (recurrent vs. de novo IIIB-IV) (p = 0.201), whether erlotinib was used as first-, second-, third-line therapy (p = 0.971) or at different doses (100 vs. 150 mg daily dose) (p = 0.579). Conclusions: OS after erlotinib use was not different, whether used as first-, second- or third-line therapy, whether patients had recurrent metastatic NSCLC or de novo stage IV disease, or if erlotinib was used at a dose of 100 or 150 mg daily.

KW - Erlotinib

KW - Metastatic non-small-cell lung cancer

KW - Non-small-cell lung cancer

KW - Tarceva

UR - http://www.scopus.com/inward/record.url?scp=58149099349&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149099349&partnerID=8YFLogxK

U2 - 10.1159/000187427

DO - 10.1159/000187427

M3 - Article

C2 - 19122466

AN - SCOPUS:58149099349

VL - 76

SP - 85

EP - 90

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 2

ER -